Insmed: AstraZeneca Exercises Exclusive Option to Advance INS1007
March 16 2020 - 5:36PM
Dow Jones News
By Stephen Nakrosis
Insmed Inc. on Monday said AstraZeneca PLC exercised an
exclusive option to "advance clinical development of INS1007 in the
indication of chronic obstructive pulmonary disease or asthma."
Under the terms of the deal, AstraZeneca is responsible for all
aspects of development up to and including Phase 2 clinical
trials.
AstraZeneca also has the option to move beyond Phase 2 clinical
trials if the company's reach agreement on commercial terms, Insmed
said.
In February 2020, Insmed reported positive top-line results from
the global Phase 2 Willow study of INS1007 in adults with
non-cystic fibrosis bronchiectasis. Insmed plans to advance INS1007
to Phase 3 development for the treatment of bronchiectasis.
Insmed is also exploring the use of INS1007 in treating acute
respiratory distress syndrome that may be brought on by any number
of causes, including in the setting of respiratory failure due to
Covid-19.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 16, 2020 17:21 ET (21:21 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024